Skip to primary navigation Skip to main content
Buffalo Local Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Newlink Genetics Cor (NQ: NLNK)
1.645 USD  -0.205 (-11.08%)
Official Closing Price  /  Updated: 5:16 PM EST, Feb 22, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 829,300
Open 1.900
Bid (Size) 1.600 (50)
Ask (Size) 1.680 (5)
Prev. Close 1.850
Today's Range 1.600 - 1.900
52wk Range 1.278 - 8.380
Shares Outstanding 37,165,098
Dividend Yield N/A
Performance
YTD
-0.90%
-0.90%
1 Month
+22.76%
+22.76%
3 Month
-15.21%
-15.21%
6 Month
-43.08%
-43.08%
1 Year
-76.50%
-76.50%
Top News
More News
NewLink Genetics to Host Its Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019
NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its fourth quarter and full year 2018 financial results on Wednesday, February 27, 2019. The company has scheduled a... Read More
from GlobeNewswire News Releases
Factors of Influence in 2019, Key Indicators and Opportunity within Marathon Oil, Accuray, United Natural Foods, Systemax, Amgen, and NewLink Genetics — New Research Emphasizes Economic Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Marathon Oil Corporation... Read More
from GlobeNewswire News Releases
More News
Read More
NewLink Genetics to Participate in the Immuno-Oncology 360° Conference
from GlobeNewswire News Releases
NewLink Genetics Announces Merck Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920 (rVSV?G-ZEBOV-GP) to U.S. Food and Drug Administration
from GlobeNewswire News Releases
NewLink Genetics Presents Phase 1 Data Supporting Significantly Higher Exposure with Indoximod Prodrug, NLG802, and Biomarker Data from Two Phase 2 Trials Illustrating Indoximod’s Impact on the Tumor
from GlobeNewswire News Releases
NewLink Genetics Announces Publication of Abstracts for Presentation at the Society for Immunotherapy for Cancer (SITC) Conference
from GlobeNewswire News Releases
Analysis: Positioning to Benefit within Mercury, Lincoln Electric, Sprint, Fred's, NewLink Genetics, and El Paso Electric — Research Highlights Growth, Revenue, and Consolidated Results
from GlobeNewswire News Releases
NewLink Genetics Presents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting
from Business Wire News Releases
CORRECTED: NewLink Genetics Reports Third Quarter 2018 Financial Results and Announces Abstracts to Be Presented at Upcoming Medical Meetings
from GlobeNewswire News Releases
NewLink Genetics Reports Third Quarter 2018 Financial Results and Announces Abstracts to Be Presented at Upcoming Medical Meetings
from GlobeNewswire News Releases
NewLink Genetics Announces Oral Presentation at the 2018 American Society of Hematology (ASH) Annual Meeting
from GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.